Intraoperative Lidocaine or Dexmedetomidine for Postoperative Pain Modulation After Urethral Reconstruction.
Effects of Intravenous Lidocaine and Dexmedetomidine Infusions on Postoperative Pain and the Development of Chronic Pain Following Urethral Reconstruction Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial.
The development of chronic postoperative pain (CPP) following surgery is influenced by several factors, among which the intensity of acute postoperative pain in the immediate perioperative period and mechanisms related to nerve fiber injury play a crucial role. Previous studies have demonstrated that factors such as the severity of early postoperative pain, patient age, and the extent of surgical intervention may increase the risk of transition from acute to chronic pain. In recent years, growing attention has been directed toward anesthetic techniques and adjuvant analgesics (co-analgesics) administered during surgery, which may potentially reduce the incidence of CPP.
The aim of this study is to evaluate the effects of intraoperative intravenous infusions of dexmedetomidine or lidocaine during urethral reconstructive surgery on postoperative pain intensity, patient-reported quality of recovery, and the incidence and characteristics of chronic postoperative pain, including its neuropathic component. In particular, the study will investigate whether administration of these agents reduces pain intensity during the first 48 hours after surgery-which, according to existing evidence, may correlate with the risk of CPP development-and whether intraoperative infusion of lidocaine or dexmedetomidine translates into reduced pain severity and a lower risk of neuropathic pain at long-term follow-up (3, 6, and 12 months after surgery).
An important aspect of this project is that both investigational drugs-lidocaine and dexmedetomidine-have an established role in routine anesthesiology practice, and their safety profiles are well characterized and extensively documented in the medical literature. Intravenous lidocaine infusion has been used for many years as part of multimodal perioperative analgesia; numerous randomized controlled trials and meta-analyses have confirmed its efficacy in reducing postoperative pain intensity and opioid requirements, with a low risk of adverse effects when administered at therapeutic doses. Dexmedetomidine has been routinely used for years both in intensive care units and as a component of general anesthesia across a wide range of surgical procedures. Its analgesic, anxiolytic, and opioid-sparing effects have been supported by a substantial body of clinical evidence, and the doses used in the present protocol are consistent with established clinical practice.
研究概览
地位
条件
详细说明
Lidocaine and dexmedetomidine are drugs with a long history of clinical use in anesthesiology and intensive care medicine, and their safety has been extensively documented. Intravenous lidocaine infusion at therapeutic doses constitutes an established component of multimodal perioperative analgesia. Its efficacy in reducing postoperative pain intensity, decreasing opioid requirements, and attenuating the inflammatory response to surgical injury has been demonstrated in numerous prospective randomized trials and meta-analyses. Dexmedetomidine, a selective α₂-adrenergic receptor agonist, is routinely used both for sedation and analgesia in intensive care units and as a component of balanced anesthesia in a wide range of surgical procedures. Its analgesic, sympatholytic, and opioid-sparing properties, together with its favorable effects on hemodynamic stability, have been supported by a substantial body of clinical evidence. The dose ranges employed in the present protocol fall within the limits recommended by current guidelines and are consistent with established clinical practice.
The objective of this study is to determine whether the pharmacological properties of these two agents may be beneficial in preventing chronic postsurgical pain in patients undergoing urethral reconstructive surgery, an area in which high-quality methodological evidence remains scarce.
b) Detailed Methodology Study population The study will enroll patients aged 18-75 years with physical status classification of American Society of Anesthesiology status (ASA) I-III who are scheduled to undergo urethral surgery (e.g., urethral reconstruction, urethroplasty, or treatment of urethral strictures).
Study Design
Recruitment
Participants will be recruited from among patients of the Department of Urology, Centre of Postgraduate Medical Education, Orlowski Hospital, Warsaw, who are scheduled for urethral reconstructive surgery. During the pre-anesthetic clinic visit or following hospital admission on the day preceding surgery, patients will receive detailed information about the study and an informed consent form for participation in the clinical trial. They will have the opportunity to ask questions and receive comprehensive answers. Signed consent forms will be collected on the morning of surgery.
- Randomization and Blinding
Patients will be randomly assigned to one of three groups:
Dexmedetomidine group: intravenous dexmedetomidine bolus of 0.6 μg/kg administered over 10 minutes before induction of anesthesia, followed by continuous infusion at 0.6 μg/kg/h until the end of surgery; Lidocaine group: intravenous lidocaine bolus of 1.5 mg/kg administered over 10 minutes before induction of anesthesia, followed by continuous infusion at 1.5 mg/kg/h until the end of surgery; Control group: placebo consisting of 0.9% sodium chloride administered according to an identical volume-based regimen.
Randomization will be performed using the website www.randomizer.org with equal allocation among the three study groups.
Blinding will be ensured using opaque, sealed envelopes containing the randomization number. The envelope will be opened immediately before preparation of the study infusion on the day of surgery, following acquisition of informed consent, by a physician who is a member of the research team but will not be involved in the patient's subsequent intraoperative or postoperative care. This physician will prepare the study medication in a 50-mL syringe according to the coded allocation:
- - dexmedetomidine 4 μg/mL
- - lidocaine 10 mg/mL
- - 0.9% sodium chloride (NaCl)
Neither the patient nor the clinical staff involved in perioperative care will be aware of treatment allocation (double-blind design).
Patient data will be collected in a secure database inaccessible to unauthorized individuals and will include demographic data (age, height, body weight, ASA status, comorbidities, substance use, location of urethral stricture), surgical data (fluid administration, duration of surgery, blood loss), and intervention-related data (total amount of study drug administered and anesthesia-related complications such as hypotension or bradycardia requiring vasoactive treatment).
3. Perioperative Management
Upon arrival in the operating room, standard monitoring of vital signs will be initiated and prophylactic antibiotics administered according to institutional protocols.
The study drug infusion will then be started at a rate of 0.9 mL/kg/h and continued for 10 minutes, corresponding to a dose of 0.6 μg/kg dexmedetomidine or 1.5 mg/kg lidocaine.
Subsequently, the infusion will be continued until placement of the final skin suture at a rate of 0.15 mL/kg/h, corresponding to 0.6 μg/kg/h dexmedetomidine or 1.5 mg/kg/h lidocaine.
General anesthesia will be induced and maintained using standard doses of opioids and anesthetic agents, with maintenance by inhalational anesthesia using sevoflurane.
Postoperatively, all patients will receive standardized multimodal analgesia consisting of paracetamol 1 g every 6 hours, metamizole 1 g every 6 hours, and intravenous dexketoprofen 50 mg three times daily. In cases of insufficient analgesia (pain intensity >3 on the Numeric Rating Scale [NRS]), buprenorphine 0.3 mg intravenously or intramuscularly will be administered at intervals no shorter than 2 hours, with an additional intravenous bolus of 0.3 mg permitted for breakthrough pain if required.
4. Assessment of Acute Pain and Quality of Recovery
During the first 48 postoperative hours, pain intensity will be assessed using the Numeric Rating Scale (NRS 0-10) both at rest and during coughing at predefined time points: 2, 4, 8, 24, and 48 hours after surgery.
Total opioid consumption (buprenorphine) during the first 24 hours and time to first opioid administration will be recorded.
Before discharge, patients will complete the Polish version of the Quality of Recovery questionnaire (QoR-15).
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Bartosz Horosz, MD,PhD
- 电话号码:0048225841122
- 邮箱:bartosz.horosz@gmail.com
研究联系人备份
- 姓名:Katarzyna Białowolska-Horosz, MD,PhD
学习地点
-
-
-
Warsaw、波兰、01-355
- Department of Anesthesiology and Intensive Care, Centre of Postgraduate Medical Education
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- ASA status less or equal 3
- Scheduled for reconstructive surgery of urethra
- Able to understand information provided and to sign informed consent for participation in the study
Exclusion Criteria:
- known allergy to one of the investigated medications
- current chronic pain
- known chronic use of opioids, gabapentinoids and antidepressants
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Perioperative lidocaine infusion
Intravenous lidocaine bolus of 1.5 mg/kg administered over 10 minutes before induction of anesthesia, followed by continuous infusion at 1.5 mg/kg/h until the end of surgery.
|
The study drug infusion will be started prior ti induction of general anesthesia at a rate of 0.9 mL/kg/h and continued for 10 minutes, corresponding to a dose of 1.5 mg/kg lidocaine.
Subsequently, the infusion will be continued until placement of the final skin suture at a rate of 0.15 mL/kg/h, corresponding to 1.5 mg/kg/h of lidocaine.
其他名称:
|
|
实验性的:Perioperative dexmedetomidine infusion
Intravenous dexmedetomidine bolus of 0.6 mcg/kg administered over 10 minutes before induction of anesthesia, followed by continuous infusion at 0.6 mcg/kg/h until the end of surgery
|
The study drug infusion will be started at a rate of 0.9 mL/kg/h and continued for 10 minutes, corresponding to a dose of 0.6 μg/kg dexmedetomidine.
Subsequently, the infusion will be continued until placement of the final skin suture at a rate of 0.15 mL/kg/h, corresponding to 0.6 mcg/kg/h of dexmedetomidine.
其他名称:
|
|
安慰剂比较:Perioperative 0.9% NaCl infusion
The infusion of 0.9% NaCl will then be started at a rate of 0.9 mL/kg/h and continued for 10 minute.
Subsequently, the infusion will be continued until placement of the final skin suture at a rate of 0.15 mL/kg/h.
|
The 0.9% NaCl infusion will be started at a rate of 0.9 mL/kg/h and continued for 10 minutes.
Subsequently, the infusion will be continued until placement of the final skin suture at a rate of 0.15 mL/kg/h.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Postoperative opioid consumption following urethral reconstructive surgery
大体时间:24 hours
|
Intravenous buprenorphine consumption
|
24 hours
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of patients with at least one episode of bradycardia
大体时间:24 hours
|
Noted episodes of bradycardia requiring administration of atropine
|
24 hours
|
|
Number of patients with at least one episode of hypotension
大体时间:24 hours
|
Noted episodes of hypotension requiring administration of vasoactive agents
|
24 hours
|
|
Intensity of postoperative pain assesses by Numeric Rating Scale (NRS, 0-10; 0 = no pain, 10 = worst pain imaginable)
大体时间:48 hours
|
Pain intensity in Numeric Rating Scale (NRS, 0-10; 0 = no pain, 10 = worst pain imaginable) at 2,4, 8, 24 and 48 hours postoperatively
|
48 hours
|
|
Time to first opioid request
大体时间:24 hours
|
The time from emergence of anesthesia to the first dose of buprenorphine
|
24 hours
|
|
Number of patients with at least one reported episode of nausea
大体时间:24 hours
|
Episodes of nausea up to 24 hours postoperatively
|
24 hours
|
|
Number of patients with at least one episode of vomiting
大体时间:24 hours
|
Episodes of vomiting up to 24 hours postoperatively
|
24 hours
|
|
Quality of Recovery - 15 score (QoR-15, 0-150, 0 = very poor recovery, 150 = excellent recovery)
大体时间:48 hours
|
Quality of Recovery -15 (QoR-15, 0-150, 0 = very poor recovery, 150 = excellent recovery) on postoperative day 2 (POD-2)
|
48 hours
|
合作者和调查者
调查人员
- 学习椅:Małgorzata Malec-Milewska, MD, Prof.、Department of Anesthesia and Intensive Care, Orlowski Hospital, Warsaw
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- BMG Neuropathic Pain
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.